MYOMO, INC.MYOEarnings & Financial Report
MYOMO, Inc. is a medical technology firm that develops and makes wearable myoelectric orthotic devices to help people with upper limb paralysis or weakness regain functional movement. Its core products serve stroke, spinal cord injury and neurological condition patients, with primary market focus across North America.
MYO Q4 FY2025 Key Financial Metrics
Revenue
$11.4M
Gross Profit
$7.8M
Operating Profit
$-2.8M
Net Profit
$-3.8M
Gross Margin
68.6%
Operating Margin
-24.4%
Net Margin
-33.6%
YoY Growth
-5.9%
EPS
$-0.09
MYOMO, INC. Q4 FY2025 Financial Summary
MYOMO, INC. reported revenue of $11.4M (down 5.9% YoY) for Q4 FY2025, with a net profit of $-3.8M (down 1366.4% YoY) (-33.6% margin). Cost of goods sold was $3.6M, operating expenses totaled $10.6M.
Key Financial Metrics
| Total Revenue | $11.4M |
|---|---|
| Net Profit | $-3.8M |
| Gross Margin | 68.6% |
| Operating Margin | -24.4% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
MYOMO, INC. Q4 FY2025 revenue of $11.4M breaks down across 2 segments, led by Direct To Patient at $7.9M (69.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Direct To Patient | $7.9M | 69.3% |
| Clinical And Medical Providers | $3.5M | 30.7% |
MYOMO, INC. Revenue by Segment — Quarterly Trend
MYOMO, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Direct To Patient and Clinical And Medical Providers) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Direct To Patient | $7.9M | $7.3M | $7.4M | $7.8M |
| Clinical And Medical Providers | $3.5M | $2.8M | $2.2M | $2.0M |
MYOMO, INC. Annual Revenue by Year
MYOMO, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $40.9M).
MYOMO, INC. Quarterly Revenue & Net Profit History
MYOMO, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $11.4M | -5.9% | $-3.8M | -33.6% |
| Q3 FY2025 | $10.1M | +9.6% | $-3.7M | -36.3% |
| Q2 FY2025 | $9.7M | +28.3% | $-4.6M | -48.0% |
| Q1 FY2025 | $9.8M | +161.9% | $-3.5M | -35.2% |
| Q4 FY2024 | $12.1M | +153.7% | $-260.1K | -2.2% |
| Q3 FY2024 | $9.2M | +81.3% | $-966.4K | -10.5% |
| Q2 FY2024 | $7.5M | +26.2% | $-1.1M | -14.9% |
| Q1 FY2024 | $3.8M | +8.9% | $-3.8M | -102.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.8M | $7.5M | $9.2M | $12.1M | $9.8M | $9.7M | $10.1M | $11.4M |
| YoY Growth | 8.9% | 26.2% | 81.3% | 153.7% | 161.9% | 28.3% | 9.6% | -5.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $16.5M | $16.2M | $16.3M | $42.2M | $40.9M | $38.7M | $34.1M | $38.6M |
| Liabilities | $5.6M | $6.5M | $7.0M | $17.5M | $19.2M | $21.1M | $19.5M | $27.2M |
| Equity | $10.9M | $9.7M | $9.3M | $24.7M | $21.7M | $17.6M | $14.6M | $11.4M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.2M | $-1.9M | $-1.5M | $3.4M | $-2.7M | $-8.9M | $-1.8M | $-1.1M |